Brokerages Set Gossamer Bio, Inc. (NASDAQ:GOSS) Price Target at $5.43

Shares of Gossamer Bio, Inc. (NASDAQ:GOSS) have earned an average rating of “Hold” from the ten analysts that are currently covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and four have issued a buy rating on the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $5.4286.

Several research analysts have issued reports on GOSS shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Gossamer Bio in a report on Thursday, January 22nd. Oppenheimer lowered their target price on Gossamer Bio from $12.00 to $3.00 and set an “outperform” rating for the company in a research note on Thursday, March 5th. Wall Street Zen downgraded Gossamer Bio from a “hold” rating to a “sell” rating in a research report on Friday, January 23rd. Barclays lowered Gossamer Bio from an “overweight” rating to an “underweight” rating in a research note on Tuesday, February 24th. Finally, Cantor Fitzgerald reiterated a “neutral” rating on shares of Gossamer Bio in a research report on Monday, March 23rd.

Institutional Investors Weigh In On Gossamer Bio

Several institutional investors have recently modified their holdings of the business. Vanguard Group Inc. lifted its holdings in Gossamer Bio by 5.2% in the third quarter. Vanguard Group Inc. now owns 12,009,773 shares of the company’s stock valued at $31,586,000 after buying an additional 598,981 shares during the period. State Street Corp raised its position in shares of Gossamer Bio by 139.7% during the 4th quarter. State Street Corp now owns 9,310,969 shares of the company’s stock valued at $28,864,000 after acquiring an additional 5,427,302 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Gossamer Bio by 3.9% during the 4th quarter. Geode Capital Management LLC now owns 4,872,714 shares of the company’s stock valued at $15,109,000 after acquiring an additional 183,183 shares during the last quarter. Corient Private Wealth LLC lifted its stake in shares of Gossamer Bio by 19,123.7% in the 4th quarter. Corient Private Wealth LLC now owns 3,845,885 shares of the company’s stock valued at $11,922,000 after purchasing an additional 3,825,879 shares during the period. Finally, Millennium Management LLC lifted its stake in shares of Gossamer Bio by 629.3% in the 3rd quarter. Millennium Management LLC now owns 3,619,329 shares of the company’s stock valued at $9,519,000 after purchasing an additional 3,123,081 shares during the period. Institutional investors and hedge funds own 81.23% of the company’s stock.

Gossamer Bio Trading Up 2.7%

GOSS opened at $0.33 on Friday. Gossamer Bio has a 1-year low of $0.32 and a 1-year high of $3.87. The stock has a market capitalization of $77.10 million, a PE ratio of -0.44 and a beta of 2.08. The firm has a 50-day moving average price of $1.35 and a two-hundred day moving average price of $2.32.

Gossamer Bio (NASDAQ:GOSS) last announced its earnings results on Tuesday, March 17th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.01). The company had revenue of $13.80 million for the quarter, compared to analyst estimates of $7.53 million. Gossamer Bio had a negative return on equity of 1,774.72% and a negative net margin of 351.49%. On average, research analysts predict that Gossamer Bio will post -0.28 EPS for the current year.

About Gossamer Bio

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company is focused on discovering and developing oral, once-daily therapies for immune-mediated and inflammatory diseases, as well as oncology indications. Gossamer Bio leverages a deep pipeline of small-molecule candidates aimed at improving patient outcomes in areas of high unmet need.

The company’s lead programs include GB004, an S1P1 receptor modulator in late-stage development for ulcerative colitis, and GB1275, a CD11b modulator being investigated in solid tumors and hematologic malignancies.